SCLP Scancell Holdings Plc

04 March 2024

Scancell Holdings plc

("Scancell" or the "Company")

Scancell to present at the Next-Gen Immuno-Oncology Conference

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that it will be presenting at the Next-Gen Immuno-Oncology Conference. The conference is being held from 7-8 March 2024 in London, UK.

Professor Lindy Durrant, Chief Executive Officer of Scancell, will be speaking at the "New Antibody Formats & Cell Therapy" session titled "A novel redirecting antibody targeting SCLC" which will take place from 2:45 pm - 3:15 pm GMT on Thursday 7 March 2024.

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "I am looking forward to presenting our preclinical results showing strong anti-tumour killing with no associated toxicity with our innovative T cell redirecting antibody at this premier event which is dedicated to advancing the field of immuno-oncology".

If you would like to arrange a meeting with management, please contact commercial.enquiries@scancell.co.uk.

-ENDS-

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/